{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:30:04Z","timestamp":1793651404805,"version":"4.5.1"},"reference-count":6,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jchf.2026.103312","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:52:01Z","timestamp":1789087921000},"page":"103312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["If Oral Inotropes Are Good Enough for Our Pets, Why Not for Our Patients With Heart Failure?"],"prefix":"10.1016","volume":"14","author":[{"given":"Sounok","family":"Sen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2026.103312_bib1","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1111\/jvim.14586","article-title":"Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC study-a randomized clinical trial","volume":"30","author":"Boswood","year":"2016","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.jchf.2026.103312_bib2","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/ejhf.1557","article-title":"Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials","volume":"21","author":"Ahmad","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2026.103312_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ehf2.12103","article-title":"Heart failure epidemiology and novel treatments in Japan: facts and numbers","volume":"3","author":"Konishi","year":"2016","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jchf.2026.103312_bib4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ejhf.2814","article-title":"Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology","volume":"25","author":"Gustafsson","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2026.103312_bib5","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007759","article-title":"Effect of inotropes on patient-reported health status in end-stage heart failure: a review of published clinical trials","volume":"14","author":"Clarke","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2026.103312_bib6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jchf.2019.12.011","article-title":"Endpoints in heart failure drug development: history and future","volume":"8","author":"Fiuzat","year":"2020","journal-title":"JACC Heart Fail"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177926004154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177926004154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:59:09Z","timestamp":1793649549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177926004154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":6,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2213177926004154"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2026.103312","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"If Oral Inotropes Are Good Enough for Our Pets, Why Not for Our Patients With Heart Failure?","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2026.103312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}],"article-number":"103312"}}